RCMG Inc. for Human Health
RCMG’s proprietary technology platform is able to continually create novel biomarkers/in vitro diagnostics (IVDs) to detect specific disease conditions suitable for the diversity of personalized medicine.
In the Glycoscience, new technologies based on engineering in addition to biochemistry and molecular biology promote new findings in medicine.
Hepatitis B virus (HBV), one of the most human infected viruses, has been a global health problem. A recombinant monoclonal antibody against HBsAg glycan isomer (HBsAgGi) was cloned and available from RCMG Inc.
Latest News
2025.1.31
RCMG Inc. is pleased to announce that the results of research using the “HBsAgGi ELISA” kit, which is available from our company, have been published in the Antiviral Research by Dr. Bilian Yao and Dr. Xinxin Zhang of Shanghai Jiao Tong University School of Medicine.
2024.8.20
RCMG Inc. is pleased to announce that the results of research using the “HBsAgGi ELISA” kit, which is available from our company, have been published in the Hepatology Research by Dr. Taiki Okumura and Prof. Takeshi Umemura of Shinshu University School of Medicine.
2024.5.28
RCMG Inc. is pleased to announce that the results of research using the “HBsAgGi ELISA” kit, which is available from our company, have been published in the Hepatology Research by Dr. Yuji Ikeda and Prof. Takuya Genda of Juntendo University Shizuoka Hospital.
2024.4.12
RCMG Inc. is pleased to announce that the poster describing on the correlation of HBsAgGi (HB surface antigen glycan isomer) with HBV-DNA and HBV-RNA virions in clinical samples was presented and received the Investigator Award at the Asian Pacific Association for the Study of the Liver (APASL) Annual Meeting 2024 (Kyoto, Mar. 27-31, 2024).
2024.2.7
RCMG Inc. is pleased to announce that the results of research using the “HBsAgGi ELISA” kit, which is available from our company, have been published in the Hepatology Research by Dr. Ritsuzo Kozuka and Dr. Masaru Enomoto of Osaka Metropolitan University.